NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis

References

• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015 Jun 10;33(17):1974–10. doi:10.1200/JCO.2014.59.4358.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000 Oct 2;192(7):1027–1034. doi:10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger, SN, Smith, DC, McDermott, DF, Powderly, JD, Carvajal, RD, Sosman, JA, Atkins, MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Abdel Hafeez LA, Mansor SG, Zahran AM. Expression of programmed death ligand-1 (PDL-1) in Acute Myeloid Leukemia patients and its relation to post induction response. SECI Oncol J. 2021;9(2):106–111.
   Google Scholar
• Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016 Apr;15(4):235–247. doi:10.1038/nrd.2015.35.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer. JAMA Oncol. 2021 May 1;7(5):709–717. doi:10.1001/jamaoncol.2021.0366.
   PubMed Web of Science ®Google Scholar
• Sheng X, Yan X, Chi Z, Si L, Cui C, Tang B, Li S, Mao L, Lian B, Wang X, et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. J Clin Oncol. 2019 Nov 10;37(32):2987–2999. doi:10.1200/JCO.19.00210.
   PubMed Web of Science ®Google Scholar
• Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, et al. ORIENT-15 study group. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022 Apr 19;377:e068714. doi:10.1136/bmj-2021-068714.
   PubMedGoogle Scholar
• Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020 Apr;21(4):571–580. doi:10.1016/S1470-2045(20)30011-5.
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Podzemny V, Castellano P, Orditura M, Napolitano V. Naples prognostic score, based on nutritional and inflammatory status, is an independent predictor of long-term outcome in patients undergoing surgery for colorectal cancer. Dis Colon Rectum. 2017 Dec;60(12):1273–1284. doi:10.1097/DCR.0000000000000961.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–247. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M, Cheng SY, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021 Jul;32(7):881–895. doi:10.1016/j.annonc.2021.04.008.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. 2021 Jul 3;Lancet. 398(10294):27–40. doi:10.1016/S0140-6736(21)00797-2.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob J-J, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, et al. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan;16(3):4429–4438. doi:10.2217/fon-2019-0666.
   PubMed Web of Science ®Google Scholar
• Kano H, Ichihara E, Harada D, Inoue K, Kayatani H, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, et al. Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status. Cancer Sci. 2020 Oct;111(10):3739–3746. doi:10.1111/cas.14590.
   PubMed Web of Science ®Google Scholar
• Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales‐Barrera R, Devitt M, Nelson A, Hoimes CJ, et al. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 Mar 15;126(6):1208–1216. doi:10.1002/cncr.32645.
   PubMed Web of Science ®Google Scholar
• Chalker C, Voutsinas JM, Wu QV, Santana‐Davila R, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, et al. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients. Cancer Med. 2022 Nov;11(22):4104–4111. doi:10.1002/cam4.4722.
   PubMed Web of Science ®Google Scholar
• Park SH, Lee S, Song JH, Choi S, Cho M, Kwon IG, Son T, Kim H-I, Cheong J-H, Hyung WJ, et al. Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. Eur J Surg Oncol. 2020 Apr;46(4):620–625. doi:10.1016/j.ejso.2019.10.024.
   PubMed Web of Science ®Google Scholar
• Zeng X, Liu G, Pan Y, Li, Y. Prognostic value of clinical biochemistry-based indexes in Nasopharyngeal Carcinoma. Front Oncol. 2020 Mar 6;10:146.
   PubMedGoogle Scholar
• Seo Y, Eo W, Kim S, Shim B, Lee S. Can nutritional status predict overall survival in patients with advanced non-small cell lung cancer? Nutr Cancer. 2019;71(7):1108–1117. doi:10.1080/01635581.2019.1598564.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jin J, Tang M, Li P, Zhou L-N, Du Y-P, Chen M-B. Prognostic nutritional index predicts outcome of PD-L1 negative and MSS advanced cancer treated with PD-1 inhibitors. Biomed Res Int. 2022 Jun 6;2022:1–9. doi:10.1155/2022/6743126.
   Web of Science ®Google Scholar
• Zhi J, Khozin S, Kuk D, Torres AZ, Sorg R, Lee SE, Miksad RA, Pazdur R, Abernethy AP. Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P). J Clin Oncol. 2018;36(15_suppl):6553–6553. doi:10.1200/JCO.2018.36.15_suppl.6553.
   Google Scholar
• Ohba T, Takamori S, Toyozawa R, Nosaki K, Umeyama Y, Haratake N, Miura N, Yamaguchi M, Taguchi K, Seto T, et al. Prognostic impact of the controlling nutritional status score in patients with non-small cell lung cancer treated with pembrolizumab. J Thorac Dis. 2019 Sep;11(9):3757–3768. doi:10.21037/jtd.2019.09.29.
   PubMed Web of Science ®Google Scholar
• Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, Educational and Clinical Practice Committee. Educational and clinical practice committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003 Aug;22(4):415–421. doi:10.1016/S0261-5614(03)00098-0.
   PubMed Web of Science ®Google Scholar
• Ding P, Guo H, Sun C, Yang P, Tian Y, Liu Y, Zhang Z, Wang D, Zhao X, Tan B, et al. Relationship between nutritional status and clinical outcome in patients with gastrointestinal stromal tumor after surgical resection. Front Nutr. 2022 Feb 2;9:818246. doi:10.3389/fnut.2022.818246.
   PubMed Web of Science ®Google Scholar
• Jia P, Wu X, Shen F, Xu G, Xu H, Cong M, Song C, Shi H. Nutritional status and its correlation to prognosis of nasopharyngeal carcinoma patients in different ages in China: a multicenter cohort study. Support Care Cancer. 2023 Oct 17;31(12):638.
   PubMed Web of Science ®Google Scholar
• Antasouras G, Papadopoulou SK, Tolia M, Pandi A-L, Spanoudaki M, Tsoukalas N, Tsourouflis G, Psara E, Mentzelou M, Giaginis C. May nutritional status positively affect disease progression and prognosis in patients with esophageal and pharyngeal cancers? A scoping review of the current clinical studies. Med Sci (Basel). 2023 Oct 2;11(4):64. doi:10.3390/medsci11040064.
   PubMedGoogle Scholar
• Wang J, Yu B, Ye Y, Shen J, Ding N, Tang H, Xu Y, Song L, Zhu Z, Chen Y, et al. Predictive value of nutritional risk screening 2002 and prognostic nutritional index for esophageal cancer patients undergoing definitive radiochemotherapy. Nutr Cancer. 2018 Aug-Sep;70(6):879–885. doi:10.1080/01635581.2018.1470656.
   PubMed Web of Science ®Google Scholar
• Chen N, Yu Y, Shen W, Xu X, Fan Y. Nutritional status as prognostic factor of advanced oesophageal cancer patients treated with immune checkpoint inhibitors. Clin Nutr. 2024 Jan;43(1):142–153. doi:10.1016/j.clnu.2023.11.030.
   PubMed Web of Science ®Google Scholar
• Li J, Yang W, Yuan Y, Zuo M, Li T, Wang Z, Liu Y. Preoperative Naples prognostic score is a reliable prognostic indicator for newly diagnosed glioblastoma patients. Front Oncol. 2022 Aug 16;12:775430. doi:10.3389/fonc.2022.775430.
   PubMed Web of Science ®Google Scholar
• Chen F, Xie C, Ren K, Xu X. Prognostic value of the Naples prognostic score in patients with gastrointestinal cancers: a meta-analysis. Nutr Cancer. 2023;75(7):1520–1530. doi:10.1080/01635581.2023.2212426.
   PubMed Web of Science ®Google Scholar
• Erin N, Grahovac J, Brozovic A, Efferth T. 2020. Dec. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 53:100715. doi:10.1016/j.drup.2020.100715.
   PubMed Web of Science ®Google Scholar
• Kim E, Ahn H, Park H. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. Mamm Genome. 2021 Aug;32(4):223–231. doi:10.1007/s00335-021-09867-3.
   PubMed Web of Science ®Google Scholar
• Shui L, Yang X, Li J, Yi C, Sun Q, Zhu H. Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy. Front Immunol. 2020 Jan 17;10:2989. doi:10.3389/fimmu.2019.02989.
   PubMed Web of Science ®Google Scholar
• Flint TR, Janowitz T, Connell CM, Roberts E, Denton A, Coll A, Jodrell D, Fearon D. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metabolism. 2016 Nov 8;24(5):672–684. doi:10.1016/j.cmet.2016.10.010.
   PubMed Web of Science ®Google Scholar
• Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016 Feb 22;5(2):e200. doi:10.1038/oncsis.2016.3.
   PubMed Web of Science ®Google Scholar
• Qu X, Tang Y, Hua S. Immunological approaches towards cancer and inflammation: a cross talk. Front Immunol. 2018 Mar 20;9:563. doi:10.3389/fimmu.2018.00563.
   PubMed Web of Science ®Google Scholar